适用于健康期婴儿的新婴儿配方奶粉:一个随机,受控,双盲,多中心,非劣质设计安全性研究
Stephen A Fleming1, Stefanie Flunkert2, Anne S Kvistgaard3
1Traverse Science, Mundelein, Illinois, United States of America.
PloS one
|December 17, 2025
概括
两种含有独特成分组合的新婴儿配方奶粉被发现与标准商业配方奶粉无差. 这些实验配方还改善了婴儿的气性和性,表明了更好的胃肠道耐受性.
科学领域:
- 婴儿营养和婴儿发育
- 婴儿的胃肠道健康 在婴儿的胃肠道健康.
- 临床试验的设计和分析.
背景情况:
- 正在开发创新的婴儿配方奶粉,以优化婴儿的生长和发育.
- 特定的成分,如益生菌,益生菌和专用脂肪,正在研究它们的益处.
- 评估新配方与既定配方的不劣势对于市场引入至关重要.
研究的目的:
- 评估两种新型婴儿配方奶粉 (BBN-001和BBN-102) 与商业标准配方奶粉相比的非劣质性.
- 为了评估人体成长,配方摄入量和胃肠道耐受性,试验配方养的婴儿.
- 分析便成分的变化,包括脂肪酸肥,作为消化健康的指标.
主要方法:
- 一个随机的,双盲的,多中心的,非劣等性研究,涉及健康的婴儿.
- 婴儿在120天内接受实验配方 (BBN-001或BBN-102) 或商业配方.
- 主要终点是体重增加;次要终点包括胃肠道耐受性和不良事件.
主要成果:
- 这两种实验配方都满足了与商业配方相比,人类测量结果的非劣等标准.
- 在配方剂摄入量,不良事件或便特征方面没有观察到显著差异.
- 实验配方显示,婴儿气性和溶性 (P < 0.05) 的测量有所改善.
- 在被试验配方养的婴儿中,便中的增加和棕酸肥的减少.
结论:
- 实验性婴儿配方奶粉耐受性良好,并证明与标准商业配方奶粉无劣.
- 新型配方对婴儿的胃肠道耐受性产生了积极影响,减少了溶性和气性.
- 这些发现支持使用具有特定成分组合的新型婴儿配方奶粉,以改善婴儿结果.
相关概念视频
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
133
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
133
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
380
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
380
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
179
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
179
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
162
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
162
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
204
Body:Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to...
204
01:13Bioequivalence studies: Biowaivers
206
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
206